Literature DB >> 1973988

Antihypertensive activity of sinorphan.

P Lefrançois, G Clerc, J Duchier, C Lim, J M Lecomte, C Gros, J C Schwartz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1973988     DOI： 10.1016/0140-6736(90)91837-z

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Therapeutic use of atrial natriuretic factor.

Authors:  J M Connell; A G Jardine; D B Northridge
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.

Authors:  S H Fettner; S Pai; G R Zhu; T Kosoglou; C R Banfield; V Batra
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 3.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

4.  Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.

Authors:  C Gros; N Noël; A Souque; J C Schwartz; D Danvy; J C Plaquevent; L Duhamel; P Duhamel; J M Lecomte; J Bralet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

5.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.